Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Accelerates Clinical Momentum After RADIANT Topline Win
Positive trial headlines and converging short-term technical signals suggest the stock may enter a controlled recovery phase while valuation metrics imply residual upside versus peers. Fundamentals show substantial cash reserves supporting upcoming registrational programs.









